Advertisement

 

 

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy.

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy.
Author Information (click to view)

Lee S, Laiman A, French MA, Flexman J, Watson MW, Price P,


Lee S, Laiman A, French MA, Flexman J, Watson MW, Price P, (click to view)

Lee S, Laiman A, French MA, Flexman J, Watson MW, Price P,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Clinical immunology (Orlando, Fla.) 2017 03 14() pii 10.1016/j.clim.2017.03.005

Abstract

Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a median (range) interval of 597 (186-766) weeks. Prior to ART, HIV/HCV patients had lower levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive neutralising antibodies (nAb) titres, than HCV patients. Levels of JFH-1 reactive antibody increased on ART, irrespective of CD4(+) T-cell counts or changes in serum ALT levels. The appearance of nAb coincided with control of HCV viral replication in five HIV/HCV patients. In other patients, HCV viral loads remained elevated despite nAb responses. Sustained virological responses following HCV therapy were associated with reduced antibody responses to JFH-1 and core but elevated responses to non-structural proteins. We conclude that nAb responses alone may fail to clear HCV, but contribute to control of viral replication in some HIV/HCV patients responding to ART.

Submit a Comment

Your email address will not be published. Required fields are marked *

13 + 8 =

[ HIDE/SHOW ]